Somatropin - Merck Serono

Drug Profile

Somatropin - Merck Serono

Alternative Names: r-hGH; Saizen; Serostim; SJ 0011; Zorbtive

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Merck Serono
  • Developer Bioject; Merck Serono; Savient Pharmaceuticals
  • Class Growth hormones; Hormonal replacements
  • Mechanism of Action Intercellular signalling peptide and protein stimulants; Somatotropin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cachexia; Short bowel syndrome; Lipodystrophy
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Cachexia; Growth disorders; Short bowel syndrome; Short stature; Somatotropin deficiency
  • Phase III Female infertility
  • Discontinued Lipodystrophy

Most Recent Events

  • 08 May 2015 AEterna Zentaris and ASCEND therapeutics agree to promote somatropin in USA
  • 01 May 2015 EMD Serono completes a phase II trial in Female infertility (Adjunctive treatment) in Canada (NCT01204840)
  • 14 Oct 2013 Savient Pharmaceuticals files for Chapter 11 bankruptcy
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top